

# Global Genetic Testing for Cancer Risk Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/GB8B3F2EE4FDEN.html>

Date: March 2023

Pages: 124

Price: US\$ 4,480.00 (Single User License)

ID: GB8B3F2EE4FDEN

## Abstracts

The global Genetic Testing for Cancer Risk market size is expected to reach \$ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Cancer risk genetic testing looks for changes in someone's genes. Genetic changes can cause some cancers. Some cancers can run in families.

This report studies the global Genetic Testing for Cancer Risk demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Genetic Testing for Cancer Risk, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Genetic Testing for Cancer Risk that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Genetic Testing for Cancer Risk total market, 2018-2029, (USD Million)

Global Genetic Testing for Cancer Risk total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Genetic Testing for Cancer Risk total market, key domestic companies and share, (USD Million)

Global Genetic Testing for Cancer Risk revenue by player and market share 2018-2023,

(USD Million)

Global Genetic Testing for Cancer Risk total market by Type, CAGR, 2018-2029, (USD Million)

Global Genetic Testing for Cancer Risk total market by Application, CAGR, 2018-2029, (USD Million)

This reports profiles major players in the global Genetic Testing for Cancer Risk market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Myriad Genetics, Inc., Invitae Corporation, Illumina, Inc., Natera, Inc., Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, CooperSurgical, Inc. and Agilent Technologies, Inc., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Genetic Testing for Cancer Risk market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Genetic Testing for Cancer Risk Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

### Global Genetic Testing for Cancer Risk Market, Segmentation by Type

Breast Cancer Risk Genetic Testing

Stomach Cancer Risk Gene Testing

Rectal Cancer Risk Genetic Testing

Others

### Global Genetic Testing for Cancer Risk Market, Segmentation by Application

Hospital

Clinic

Laboratory

### Companies Profiled:

Myriad Genetics, Inc.

Invitae Corporation

Illumina, Inc.

Natera, Inc.

Laboratory Corporation of America Holdings

F. Hoffmann-La Roche Ltd

Quest Diagnostics Incorporated

CooperSurgical, Inc.

Agilent Technologies, Inc.

Thermo Fisher Scientific, Inc.

Twist Bioscience

Sophia Genetics

Fulgent Genetic, Inc.

Medgenome

CENTOGENE

CeGaT

LifeLabs Genetics

Ambry Genetics

## Key Questions Answered

1. How big is the global Genetic Testing for Cancer Risk market?
2. What is the demand of the global Genetic Testing for Cancer Risk market?
3. What is the year over year growth of the global Genetic Testing for Cancer Risk market?
4. What is the total value of the global Genetic Testing for Cancer Risk market?

5. Who are the major players in the global Genetic Testing for Cancer Risk market?
6. What are the growth factors driving the market demand?

## Contents

### 1 SUPPLY SUMMARY

- 1.1 Genetic Testing for Cancer Risk Introduction
- 1.2 World Genetic Testing for Cancer Risk Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Genetic Testing for Cancer Risk Total Market by Region (by Headquarter Location)
  - 1.3.1 World Genetic Testing for Cancer Risk Market Size by Region (2018-2029), (by Headquarter Location)
  - 1.3.2 United States Genetic Testing for Cancer Risk Market Size (2018-2029)
  - 1.3.3 China Genetic Testing for Cancer Risk Market Size (2018-2029)
  - 1.3.4 Europe Genetic Testing for Cancer Risk Market Size (2018-2029)
  - 1.3.5 Japan Genetic Testing for Cancer Risk Market Size (2018-2029)
  - 1.3.6 South Korea Genetic Testing for Cancer Risk Market Size (2018-2029)
  - 1.3.7 ASEAN Genetic Testing for Cancer Risk Market Size (2018-2029)
  - 1.3.8 India Genetic Testing for Cancer Risk Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
  - 1.4.1 Genetic Testing for Cancer Risk Market Drivers
  - 1.4.2 Factors Affecting Demand
  - 1.4.3 Genetic Testing for Cancer Risk Major Market Trends
- 1.5 Influence of COVID-19 and Russia-Ukraine War
  - 1.5.1 Influence of COVID-19
  - 1.5.2 Influence of Russia-Ukraine War

### 2 DEMAND SUMMARY

- 2.1 World Genetic Testing for Cancer Risk Consumption Value (2018-2029)
- 2.2 World Genetic Testing for Cancer Risk Consumption Value by Region
  - 2.2.1 World Genetic Testing for Cancer Risk Consumption Value by Region (2018-2023)
  - 2.2.2 World Genetic Testing for Cancer Risk Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Genetic Testing for Cancer Risk Consumption Value (2018-2029)
- 2.4 China Genetic Testing for Cancer Risk Consumption Value (2018-2029)
- 2.5 Europe Genetic Testing for Cancer Risk Consumption Value (2018-2029)
- 2.6 Japan Genetic Testing for Cancer Risk Consumption Value (2018-2029)
- 2.7 South Korea Genetic Testing for Cancer Risk Consumption Value (2018-2029)

- 2.8 ASEAN Genetic Testing for Cancer Risk Consumption Value (2018-2029)
- 2.9 India Genetic Testing for Cancer Risk Consumption Value (2018-2029)

### **3 WORLD GENETIC TESTING FOR CANCER RISK COMPANIES COMPETITIVE ANALYSIS**

- 3.1 World Genetic Testing for Cancer Risk Revenue by Player (2018-2023)
- 3.2 Industry Rank and Concentration Rate (CR)
  - 3.2.1 Global Genetic Testing for Cancer Risk Industry Rank of Major Players
  - 3.2.2 Global Concentration Ratios (CR4) for Genetic Testing for Cancer Risk in 2022
  - 3.2.3 Global Concentration Ratios (CR8) for Genetic Testing for Cancer Risk in 2022
- 3.3 Genetic Testing for Cancer Risk Company Evaluation Quadrant
- 3.4 Genetic Testing for Cancer Risk Market: Overall Company Footprint Analysis
  - 3.4.1 Genetic Testing for Cancer Risk Market: Region Footprint
  - 3.4.2 Genetic Testing for Cancer Risk Market: Company Product Type Footprint
  - 3.4.3 Genetic Testing for Cancer Risk Market: Company Product Application Footprint
- 3.5 Competitive Environment
  - 3.5.1 Historical Structure of the Industry
  - 3.5.2 Barriers of Market Entry
  - 3.5.3 Factors of Competition
- 3.6 Mergers, Acquisitions Activity

### **4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)**

- 4.1 United States VS China: Genetic Testing for Cancer Risk Revenue Comparison (by Headquarter Location)
  - 4.1.1 United States VS China: Genetic Testing for Cancer Risk Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
  - 4.1.2 United States VS China: Genetic Testing for Cancer Risk Revenue Market Share Comparison (2018 & 2022 & 2029)
- 4.2 United States Based Companies VS China Based Companies: Genetic Testing for Cancer Risk Consumption Value Comparison
  - 4.2.1 United States VS China: Genetic Testing for Cancer Risk Consumption Value Comparison (2018 & 2022 & 2029)
  - 4.2.2 United States VS China: Genetic Testing for Cancer Risk Consumption Value Market Share Comparison (2018 & 2022 & 2029)
- 4.3 United States Based Genetic Testing for Cancer Risk Companies and Market Share, 2018-2023

4.3.1 United States Based Genetic Testing for Cancer Risk Companies, Headquarters (States, Country)

4.3.2 United States Based Companies Genetic Testing for Cancer Risk Revenue, (2018-2023)

4.4 China Based Companies Genetic Testing for Cancer Risk Revenue and Market Share, 2018-2023

4.4.1 China Based Genetic Testing for Cancer Risk Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Genetic Testing for Cancer Risk Revenue, (2018-2023)

4.5 Rest of World Based Genetic Testing for Cancer Risk Companies and Market Share, 2018-2023

4.5.1 Rest of World Based Genetic Testing for Cancer Risk Companies, Headquarters (States, Country)

4.5.2 Rest of World Based Companies Genetic Testing for Cancer Risk Revenue, (2018-2023)

## **5 MARKET ANALYSIS BY TYPE**

5.1 World Genetic Testing for Cancer Risk Market Size Overview by Type: 2018 VS 2022 VS 2029

5.2 Segment Introduction by Type

5.2.1 Breast Cancer Risk Genetic Testing

5.2.2 Stomach Cancer Risk Gene Testing

5.2.3 Rectal Cancer Risk Genetic Testing

5.2.4 Others

5.3 Market Segment by Type

5.3.1 World Genetic Testing for Cancer Risk Market Size by Type (2018-2023)

5.3.2 World Genetic Testing for Cancer Risk Market Size by Type (2024-2029)

5.3.3 World Genetic Testing for Cancer Risk Market Size Market Share by Type (2018-2029)

## **6 MARKET ANALYSIS BY APPLICATION**

6.1 World Genetic Testing for Cancer Risk Market Size Overview by Application: 2018 VS 2022 VS 2029

6.2 Segment Introduction by Application

6.2.1 Hospital

6.2.2 Clinic

6.2.3 Laboratory



## 6.3 Market Segment by Application

6.3.1 World Genetic Testing for Cancer Risk Market Size by Application (2018-2023)

6.3.2 World Genetic Testing for Cancer Risk Market Size by Application (2024-2029)

6.3.3 World Genetic Testing for Cancer Risk Market Size by Application (2018-2029)

## 7 COMPANY PROFILES

### 7.1 Myriad Genetics, Inc.

7.1.1 Myriad Genetics, Inc. Details

7.1.2 Myriad Genetics, Inc. Major Business

7.1.3 Myriad Genetics, Inc. Genetic Testing for Cancer Risk Product and Services

7.1.4 Myriad Genetics, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)

7.1.5 Myriad Genetics, Inc. Recent Developments/Updates

7.1.6 Myriad Genetics, Inc. Competitive Strengths & Weaknesses

### 7.2 Invitae Corporation

7.2.1 Invitae Corporation Details

7.2.2 Invitae Corporation Major Business

7.2.3 Invitae Corporation Genetic Testing for Cancer Risk Product and Services

7.2.4 Invitae Corporation Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)

7.2.5 Invitae Corporation Recent Developments/Updates

7.2.6 Invitae Corporation Competitive Strengths & Weaknesses

### 7.3 Illumina, Inc.

7.3.1 Illumina, Inc. Details

7.3.2 Illumina, Inc. Major Business

7.3.3 Illumina, Inc. Genetic Testing for Cancer Risk Product and Services

7.3.4 Illumina, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)

7.3.5 Illumina, Inc. Recent Developments/Updates

7.3.6 Illumina, Inc. Competitive Strengths & Weaknesses

### 7.4 Natera, Inc.

7.4.1 Natera, Inc. Details

7.4.2 Natera, Inc. Major Business

7.4.3 Natera, Inc. Genetic Testing for Cancer Risk Product and Services

7.4.4 Natera, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)

7.4.5 Natera, Inc. Recent Developments/Updates

7.4.6 Natera, Inc. Competitive Strengths & Weaknesses

## 7.5 Laboratory Corporation of America Holdings

7.5.1 Laboratory Corporation of America Holdings Details

7.5.2 Laboratory Corporation of America Holdings Major Business

7.5.3 Laboratory Corporation of America Holdings Genetic Testing for Cancer Risk Product and Services

7.5.4 Laboratory Corporation of America Holdings Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)

7.5.5 Laboratory Corporation of America Holdings Recent Developments/Updates

7.5.6 Laboratory Corporation of America Holdings Competitive Strengths & Weaknesses

## 7.6 F. Hoffmann-La Roche Ltd

7.6.1 F. Hoffmann-La Roche Ltd Details

7.6.2 F. Hoffmann-La Roche Ltd Major Business

7.6.3 F. Hoffmann-La Roche Ltd Genetic Testing for Cancer Risk Product and Services

7.6.4 F. Hoffmann-La Roche Ltd Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)

7.6.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates

7.6.6 F. Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses

## 7.7 Quest Diagnostics Incorporated

7.7.1 Quest Diagnostics Incorporated Details

7.7.2 Quest Diagnostics Incorporated Major Business

7.7.3 Quest Diagnostics Incorporated Genetic Testing for Cancer Risk Product and Services

7.7.4 Quest Diagnostics Incorporated Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)

7.7.5 Quest Diagnostics Incorporated Recent Developments/Updates

7.7.6 Quest Diagnostics Incorporated Competitive Strengths & Weaknesses

## 7.8 CooperSurgical, Inc.

7.8.1 CooperSurgical, Inc. Details

7.8.2 CooperSurgical, Inc. Major Business

7.8.3 CooperSurgical, Inc. Genetic Testing for Cancer Risk Product and Services

7.8.4 CooperSurgical, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)

7.8.5 CooperSurgical, Inc. Recent Developments/Updates

7.8.6 CooperSurgical, Inc. Competitive Strengths & Weaknesses

## 7.9 Agilent Technologies, Inc.

7.9.1 Agilent Technologies, Inc. Details

7.9.2 Agilent Technologies, Inc. Major Business

- 7.9.3 Agilent Technologies, Inc. Genetic Testing for Cancer Risk Product and Services
- 7.9.4 Agilent Technologies, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
- 7.9.5 Agilent Technologies, Inc. Recent Developments/Updates
- 7.9.6 Agilent Technologies, Inc. Competitive Strengths & Weaknesses
- 7.10 Thermo Fisher Scientific, Inc.
  - 7.10.1 Thermo Fisher Scientific, Inc. Details
  - 7.10.2 Thermo Fisher Scientific, Inc. Major Business
  - 7.10.3 Thermo Fisher Scientific, Inc. Genetic Testing for Cancer Risk Product and Services
  - 7.10.4 Thermo Fisher Scientific, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
  - 7.10.5 Thermo Fisher Scientific, Inc. Recent Developments/Updates
  - 7.10.6 Thermo Fisher Scientific, Inc. Competitive Strengths & Weaknesses
- 7.11 Twist Bioscience
  - 7.11.1 Twist Bioscience Details
  - 7.11.2 Twist Bioscience Major Business
  - 7.11.3 Twist Bioscience Genetic Testing for Cancer Risk Product and Services
  - 7.11.4 Twist Bioscience Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
  - 7.11.5 Twist Bioscience Recent Developments/Updates
  - 7.11.6 Twist Bioscience Competitive Strengths & Weaknesses
- 7.12 Sophia Genetics
  - 7.12.1 Sophia Genetics Details
  - 7.12.2 Sophia Genetics Major Business
  - 7.12.3 Sophia Genetics Genetic Testing for Cancer Risk Product and Services
  - 7.12.4 Sophia Genetics Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
  - 7.12.5 Sophia Genetics Recent Developments/Updates
  - 7.12.6 Sophia Genetics Competitive Strengths & Weaknesses
- 7.13 Fulgent Genetic, Inc.
  - 7.13.1 Fulgent Genetic, Inc. Details
  - 7.13.2 Fulgent Genetic, Inc. Major Business
  - 7.13.3 Fulgent Genetic, Inc. Genetic Testing for Cancer Risk Product and Services
  - 7.13.4 Fulgent Genetic, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
  - 7.13.5 Fulgent Genetic, Inc. Recent Developments/Updates
  - 7.13.6 Fulgent Genetic, Inc. Competitive Strengths & Weaknesses
- 7.14 Medgenome

- 7.14.1 Medgenome Details
- 7.14.2 Medgenome Major Business
- 7.14.3 Medgenome Genetic Testing for Cancer Risk Product and Services
- 7.14.4 Medgenome Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
- 7.14.5 Medgenome Recent Developments/Updates
- 7.14.6 Medgenome Competitive Strengths & Weaknesses
- 7.15 CENTOGENE
  - 7.15.1 CENTOGENE Details
  - 7.15.2 CENTOGENE Major Business
  - 7.15.3 CENTOGENE Genetic Testing for Cancer Risk Product and Services
  - 7.15.4 CENTOGENE Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
  - 7.15.5 CENTOGENE Recent Developments/Updates
  - 7.15.6 CENTOGENE Competitive Strengths & Weaknesses
- 7.16 CeGaT
  - 7.16.1 CeGaT Details
  - 7.16.2 CeGaT Major Business
  - 7.16.3 CeGaT Genetic Testing for Cancer Risk Product and Services
  - 7.16.4 CeGaT Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
  - 7.16.5 CeGaT Recent Developments/Updates
  - 7.16.6 CeGaT Competitive Strengths & Weaknesses
- 7.17 LifeLabs Genetics
  - 7.17.1 LifeLabs Genetics Details
  - 7.17.2 LifeLabs Genetics Major Business
  - 7.17.3 LifeLabs Genetics Genetic Testing for Cancer Risk Product and Services
  - 7.17.4 LifeLabs Genetics Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
  - 7.17.5 LifeLabs Genetics Recent Developments/Updates
  - 7.17.6 LifeLabs Genetics Competitive Strengths & Weaknesses
- 7.18 Ambry Genetics
  - 7.18.1 Ambry Genetics Details
  - 7.18.2 Ambry Genetics Major Business
  - 7.18.3 Ambry Genetics Genetic Testing for Cancer Risk Product and Services
  - 7.18.4 Ambry Genetics Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
  - 7.18.5 Ambry Genetics Recent Developments/Updates
  - 7.18.6 Ambry Genetics Competitive Strengths & Weaknesses

## **8 INDUSTRY CHAIN ANALYSIS**

- 8.1 Genetic Testing for Cancer Risk Industry Chain
- 8.2 Genetic Testing for Cancer Risk Upstream Analysis
- 8.3 Genetic Testing for Cancer Risk Midstream Analysis
- 8.4 Genetic Testing for Cancer Risk Downstream Analysis

## **9 RESEARCH FINDINGS AND CONCLUSION**

## **10 APPENDIX**

- 10.1 Methodology
- 10.2 Research Process and Data Source
- 10.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. World Genetic Testing for Cancer Risk Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Table 2. World Genetic Testing for Cancer Risk Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)

Table 3. World Genetic Testing for Cancer Risk Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)

Table 4. World Genetic Testing for Cancer Risk Revenue Market Share by Region (2018-2023), (by Headquarter Location)

Table 5. World Genetic Testing for Cancer Risk Revenue Market Share by Region (2024-2029), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Genetic Testing for Cancer Risk Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)

Table 8. World Genetic Testing for Cancer Risk Consumption Value by Region (2018-2023) & (USD Million)

Table 9. World Genetic Testing for Cancer Risk Consumption Value Forecast by Region (2024-2029) & (USD Million)

Table 10. World Genetic Testing for Cancer Risk Revenue by Player (2018-2023) & (USD Million)

Table 11. Revenue Market Share of Key Genetic Testing for Cancer Risk Players in 2022

Table 12. World Genetic Testing for Cancer Risk Industry Rank of Major Player, Based on Revenue in 2022

Table 13. Global Genetic Testing for Cancer Risk Company Evaluation Quadrant

Table 14. Head Office of Key Genetic Testing for Cancer Risk Player

Table 15. Genetic Testing for Cancer Risk Market: Company Product Type Footprint

Table 16. Genetic Testing for Cancer Risk Market: Company Product Application Footprint

Table 17. Genetic Testing for Cancer Risk Mergers & Acquisitions Activity

Table 18. United States VS China Genetic Testing for Cancer Risk Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 19. United States VS China Genetic Testing for Cancer Risk Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 20. United States Based Genetic Testing for Cancer Risk Companies, Headquarters (States, Country)



Table 21. United States Based Companies Genetic Testing for Cancer Risk Revenue, (2018-2023) & (USD Million)

Table 22. United States Based Companies Genetic Testing for Cancer Risk Revenue Market Share (2018-2023)

Table 23. China Based Genetic Testing for Cancer Risk Companies, Headquarters (Province, Country)

Table 24. China Based Companies Genetic Testing for Cancer Risk Revenue, (2018-2023) & (USD Million)

Table 25. China Based Companies Genetic Testing for Cancer Risk Revenue Market Share (2018-2023)

Table 26. Rest of World Based Genetic Testing for Cancer Risk Companies, Headquarters (States, Country)

Table 27. Rest of World Based Companies Genetic Testing for Cancer Risk Revenue, (2018-2023) & (USD Million)

Table 28. Rest of World Based Companies Genetic Testing for Cancer Risk Revenue Market Share (2018-2023)

Table 29. World Genetic Testing for Cancer Risk Market Size by Type, (USD Million), 2018 & 2022 & 2029

Table 30. World Genetic Testing for Cancer Risk Market Size by Type (2018-2023) & (USD Million)

Table 31. World Genetic Testing for Cancer Risk Market Size by Type (2024-2029) & (USD Million)

Table 32. World Genetic Testing for Cancer Risk Market Size by Application, (USD Million), 2018 & 2022 & 2029

Table 33. World Genetic Testing for Cancer Risk Market Size by Application (2018-2023) & (USD Million)

Table 34. World Genetic Testing for Cancer Risk Market Size by Application (2024-2029) & (USD Million)

Table 35. Myriad Genetics, Inc. Basic Information, Area Served and Competitors

Table 36. Myriad Genetics, Inc. Major Business

Table 37. Myriad Genetics, Inc. Genetic Testing for Cancer Risk Product and Services

Table 38. Myriad Genetics, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 39. Myriad Genetics, Inc. Recent Developments/Updates

Table 40. Myriad Genetics, Inc. Competitive Strengths & Weaknesses

Table 41. Invitae Corporation Basic Information, Area Served and Competitors

Table 42. Invitae Corporation Major Business

Table 43. Invitae Corporation Genetic Testing for Cancer Risk Product and Services

Table 44. Invitae Corporation Genetic Testing for Cancer Risk Revenue, Gross Margin

and Market Share (2018-2023) & (USD Million)

Table 45. Invitae Corporation Recent Developments/Updates

Table 46. Invitae Corporation Competitive Strengths & Weaknesses

Table 47. Illumina, Inc. Basic Information, Area Served and Competitors

Table 48. Illumina, Inc. Major Business

Table 49. Illumina, Inc. Genetic Testing for Cancer Risk Product and Services

Table 50. Illumina, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 51. Illumina, Inc. Recent Developments/Updates

Table 52. Illumina, Inc. Competitive Strengths & Weaknesses

Table 53. Natera, Inc. Basic Information, Area Served and Competitors

Table 54. Natera, Inc. Major Business

Table 55. Natera, Inc. Genetic Testing for Cancer Risk Product and Services

Table 56. Natera, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 57. Natera, Inc. Recent Developments/Updates

Table 58. Natera, Inc. Competitive Strengths & Weaknesses

Table 59. Laboratory Corporation of America Holdings Basic Information, Area Served and Competitors

Table 60. Laboratory Corporation of America Holdings Major Business

Table 61. Laboratory Corporation of America Holdings Genetic Testing for Cancer Risk Product and Services

Table 62. Laboratory Corporation of America Holdings Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 63. Laboratory Corporation of America Holdings Recent Developments/Updates

Table 64. Laboratory Corporation of America Holdings Competitive Strengths & Weaknesses

Table 65. F. Hoffmann-La Roche Ltd Basic Information, Area Served and Competitors

Table 66. F. Hoffmann-La Roche Ltd Major Business

Table 67. F. Hoffmann-La Roche Ltd Genetic Testing for Cancer Risk Product and Services

Table 68. F. Hoffmann-La Roche Ltd Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 69. F. Hoffmann-La Roche Ltd Recent Developments/Updates

Table 70. F. Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses

Table 71. Quest Diagnostics Incorporated Basic Information, Area Served and Competitors

Table 72. Quest Diagnostics Incorporated Major Business

Table 73. Quest Diagnostics Incorporated Genetic Testing for Cancer Risk Product and



## Services

Table 74. Quest Diagnostics Incorporated Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 75. Quest Diagnostics Incorporated Recent Developments/Updates

Table 76. Quest Diagnostics Incorporated Competitive Strengths & Weaknesses

Table 77. CooperSurgical, Inc. Basic Information, Area Served and Competitors

Table 78. CooperSurgical, Inc. Major Business

Table 79. CooperSurgical, Inc. Genetic Testing for Cancer Risk Product and Services

Table 80. CooperSurgical, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 81. CooperSurgical, Inc. Recent Developments/Updates

Table 82. CooperSurgical, Inc. Competitive Strengths & Weaknesses

Table 83. Agilent Technologies, Inc. Basic Information, Area Served and Competitors

Table 84. Agilent Technologies, Inc. Major Business

Table 85. Agilent Technologies, Inc. Genetic Testing for Cancer Risk Product and Services

Table 86. Agilent Technologies, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 87. Agilent Technologies, Inc. Recent Developments/Updates

Table 88. Agilent Technologies, Inc. Competitive Strengths & Weaknesses

Table 89. Thermo Fisher Scientific, Inc. Basic Information, Area Served and Competitors

Table 90. Thermo Fisher Scientific, Inc. Major Business

Table 91. Thermo Fisher Scientific, Inc. Genetic Testing for Cancer Risk Product and Services

Table 92. Thermo Fisher Scientific, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 93. Thermo Fisher Scientific, Inc. Recent Developments/Updates

Table 94. Thermo Fisher Scientific, Inc. Competitive Strengths & Weaknesses

Table 95. Twist Bioscience Basic Information, Area Served and Competitors

Table 96. Twist Bioscience Major Business

Table 97. Twist Bioscience Genetic Testing for Cancer Risk Product and Services

Table 98. Twist Bioscience Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 99. Twist Bioscience Recent Developments/Updates

Table 100. Twist Bioscience Competitive Strengths & Weaknesses

Table 101. Sophia Genetics Basic Information, Area Served and Competitors

Table 102. Sophia Genetics Major Business

Table 103. Sophia Genetics Genetic Testing for Cancer Risk Product and Services

- Table 104. Sophia Genetics Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 105. Sophia Genetics Recent Developments/Updates
- Table 106. Sophia Genetics Competitive Strengths & Weaknesses
- Table 107. Fulgent Genetic, Inc. Basic Information, Area Served and Competitors
- Table 108. Fulgent Genetic, Inc. Major Business
- Table 109. Fulgent Genetic, Inc. Genetic Testing for Cancer Risk Product and Services
- Table 110. Fulgent Genetic, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 111. Fulgent Genetic, Inc. Recent Developments/Updates
- Table 112. Fulgent Genetic, Inc. Competitive Strengths & Weaknesses
- Table 113. Medgenome Basic Information, Area Served and Competitors
- Table 114. Medgenome Major Business
- Table 115. Medgenome Genetic Testing for Cancer Risk Product and Services
- Table 116. Medgenome Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 117. Medgenome Recent Developments/Updates
- Table 118. Medgenome Competitive Strengths & Weaknesses
- Table 119. CENTOGENE Basic Information, Area Served and Competitors
- Table 120. CENTOGENE Major Business
- Table 121. CENTOGENE Genetic Testing for Cancer Risk Product and Services
- Table 122. CENTOGENE Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 123. CENTOGENE Recent Developments/Updates
- Table 124. CENTOGENE Competitive Strengths & Weaknesses
- Table 125. CeGaT Basic Information, Area Served and Competitors
- Table 126. CeGaT Major Business
- Table 127. CeGaT Genetic Testing for Cancer Risk Product and Services
- Table 128. CeGaT Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 129. CeGaT Recent Developments/Updates
- Table 130. CeGaT Competitive Strengths & Weaknesses
- Table 131. LifeLabs Genetics Basic Information, Area Served and Competitors
- Table 132. LifeLabs Genetics Major Business
- Table 133. LifeLabs Genetics Genetic Testing for Cancer Risk Product and Services
- Table 134. LifeLabs Genetics Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
- Table 135. LifeLabs Genetics Recent Developments/Updates
- Table 136. Ambry Genetics Basic Information, Area Served and Competitors

Table 137. Ambry Genetics Major Business

Table 138. Ambry Genetics Genetic Testing for Cancer Risk Product and Services

Table 139. Ambry Genetics Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 140. Global Key Players of Genetic Testing for Cancer Risk Upstream (Raw Materials)

Table 141. Genetic Testing for Cancer Risk Typical Customers

## List Of Figures

### LIST OF FIGURES

Figure 1. Genetic Testing for Cancer Risk Picture

Figure 2. World Genetic Testing for Cancer Risk Total Market Size: 2018 & 2022 & 2029, (USD Million)

Figure 3. World Genetic Testing for Cancer Risk Total Market Size (2018-2029) & (USD Million)

Figure 4. World Genetic Testing for Cancer Risk Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)

Figure 5. World Genetic Testing for Cancer Risk Revenue Market Share by Region (2018-2029), (by Headquarter Location)

Figure 6. United States Based Company Genetic Testing for Cancer Risk Revenue (2018-2029) & (USD Million)

Figure 7. China Based Company Genetic Testing for Cancer Risk Revenue (2018-2029) & (USD Million)

Figure 8. Europe Based Company Genetic Testing for Cancer Risk Revenue (2018-2029) & (USD Million)

Figure 9. Japan Based Company Genetic Testing for Cancer Risk Revenue (2018-2029) & (USD Million)

Figure 10. South Korea Based Company Genetic Testing for Cancer Risk Revenue (2018-2029) & (USD Million)

Figure 11. ASEAN Based Company Genetic Testing for Cancer Risk Revenue (2018-2029) & (USD Million)

Figure 12. India Based Company Genetic Testing for Cancer Risk Revenue (2018-2029) & (USD Million)

Figure 13. Genetic Testing for Cancer Risk Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 16. World Genetic Testing for Cancer Risk Consumption Value Market Share by Region (2018-2029)

Figure 17. United States Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 18. China Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 23. India Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Genetic Testing for Cancer Risk by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Genetic Testing for Cancer Risk Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Genetic Testing for Cancer Risk Markets in 2022

Figure 27. United States VS China: Genetic Testing for Cancer Risk Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Genetic Testing for Cancer Risk Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Genetic Testing for Cancer Risk Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Genetic Testing for Cancer Risk Market Size Market Share by Type in 2022

Figure 31. Breast Cancer Risk Genetic Testing

Figure 32. Stomach Cancer Risk Gene Testing

Figure 33. Rectal Cancer Risk Genetic Testing

Figure 34. Others

Figure 35. World Genetic Testing for Cancer Risk Market Size Market Share by Type (2018-2029)

Figure 36. World Genetic Testing for Cancer Risk Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 37. World Genetic Testing for Cancer Risk Market Size Market Share by Application in 2022

Figure 38. Hospital

Figure 39. Clinic

Figure 40. Laboratory

Figure 41. Genetic Testing for Cancer Risk Industrial Chain

Figure 42. Methodology

Figure 43. Research Process and Data Source

## I would like to order

Product name: Global Genetic Testing for Cancer Risk Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/GB8B3F2EE4FDEN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB8B3F2EE4FDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970